Tracy Hicks, APRN
Psychiatric/Mental Health · Longview, TXNPI 1215353651
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $491,523 of the $683,936 with a category attached, or 71.9%. 22 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 49.4% of the total. 2025 is the largest year on record at $269,985, more than ten times the $12,594 reported in 2021. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,232 payments — averaging $555.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$338K
- E.r. Squibb & Sons, L.L.C.$152K
- Teva Pharmaceuticals USA, Inc.$102K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$61K
- Alkermes, Inc.$28K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$435
- plus $2K from 16 others
What the payments were for
- Consulting fees$87,31113%
- Speaking & faculty fees$491,52372%
- Travel & lodging$77,78211%
- Food & beverage$27,1194%
- Education$2010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 459 | $338,053 |
| E.r. Squibb & Sons, L.L.C. | 201 | $151,984 |
| Teva Pharmaceuticals USA, Inc. | 262 | $101,922 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 111 | $61,230 |
| Alkermes, Inc. | 100 | $28,117 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $435 |
| Johnson & Johnson | 14 | $388 |
| Otsuka America Pharmaceutical, Inc. | 13 | $272 |
| Vanda Pharmaceuticals Inc. | 12 | $264 |
| AbbVie | 17 | $197 |
| Gilead | 4 | $164 |
| Acella Pharmaceuticals, LLC | 1 | $130 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $126 |
| Noven Therapeutics, LLC | 6 | $123 |
| Indivior Inc. | 6 | $117 |
| Axsome Therapeutics, Inc. | 6 | $116 |
| Lundbeck LLC | 6 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Abbott | 2 | $48 |
| Sunovion Pharmaceuticals Inc. | 2 | $41 |
| Eisai Inc. | 1 | $22 |
| OWP Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$330,188
- LYBALVI$102,634
- COBENFY$100,511
- UZEDY$73,167
- CAPLYTA$59,655
- Austedo XR$22,575
- ARISTADA$4,028
- AUSTEDO$1,100
- ARISTADA INITIO$900
- NP Thyroid 60$130
- NEFFY$126
- Epclusa$119
- INVEGA SUSTENNA$112
How this compares
$683,936 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 195 | $1,612,289 |
| Austedo XrDeutetrabenazine | 76 | $634,055 |
| UzedyRisperidone | 122 | $391,744 |
| AustedoDeutetrabenazine | 40 | $306,434 |
| LybalviOlanzapine/Samidorphan Malate | 80 | $134,281 |
| CaplytaLumateperone Tosylate | 31 | $54,463 |
| TrintellixVortioxetine Hydrobromide | 93 | $47,577 |
| AristadaAripiprazole Lauroxil | 12 | $43,155 |
| AuvelityDextromethorphan Hbr/Bupropion | 20 | $22,972 |
| RexultiBrexpiprazole | 15 | $22,938 |
| Lamotrigine OdtLamotrigine | 53 | $18,314 |
| SpravatoEsketamine Hcl | 13 | $12,698 |
| AbilifyAripiprazole | 15 | $12,348 |
| Oxcarbazepine | 45 | $5,541 |
| Bromocriptine Mesylate | 12 | $5,187 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $338,053 | $1,612,289195 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy, Austedo | $101,922 | $1,332,233238 claims |
| Alkermes, Inc.Lybalvi, Aristada | $28,117 | $177,43692 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $61,230 | $54,46331 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $53 | $47,57793 claims |
| Axsome Therapeutics, Inc.Auvelity | $116 | $22,97220 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $272 | $22,93815 claims |
| Johnson & JohnsonSpravato | $388 | $12,69813 claims |
| E.r. Squibb & Sons, L.L.C.Abilify | $151,984 | $12,34815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Longview
- Tracy TaylorLongview$14K
- Wendy RogersLongview$13K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.